BRIEF—Takeda gets MHRA approval for lanadelumab in younger children

The UK subsidiary of Japanese pharma major Takeda has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for lanadelumab (trademarked Takhzyro) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged two years to less than 12.

This expands the drug’s initial approved use in pediatric patients and making it the first long-term prophylactic treatment of HAE available in the UK for patients aged two to under six.

“The announcement that children under 12 now have access to this treatment option will be looked back on as a huge milestone for the HAE community. It is vitally important that those with HAE who are most vulnerable – no matter how small in number – are looked after,” said Angela Metcalfe, chief executive of HAE UK.